{
    "nctId": "NCT02437318",
    "briefTitle": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.",
    "officialTitle": "A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 572,
    "primaryOutcomeMeasure": "Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* If female, patient is postmenopausal\n* Patient has identified PIK3CA status\n* Patients may be:\n\n  * relapsed with documented evidence of progression while on (neo) adjuvant endocrine therapy or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease;\n  * relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently; progressed with documented evidence of progression while on or after only one line of endocrine therapy for metastatic disease;\n  * newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy\n* Patient has recurrence or progression of disease during or after AI therapy (i.e.\n\nletrozole, anastrozole, exemestane).\n\n* Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by local laboratory and has HER2 negative breast cancer\n* Patient has either measurable disease per RECIST 1.1 criteria OR at least one predominantly lytic bone lesion must be present\n* Patient has adequate bone marrow function\n\nExclusion Criteria:\n\n* Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment\n* Patient has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor (pre-treatment with CDK4/6 inhibitors is allowed)\n* Patient with inflammatory breast cancer at screening\n* Patients with Child pugh score B or C\n* Patients with an established diagnosis of diabetes mellitus type I or not controlled type II\n* Patient has Eastern Cooperative Oncology Group (ECOG) performance status 2 or more\n* Patient with CNS involvement unless he/she is at least 4 weeks from prior therapy completion to starting the study treatment and has stable CNS tumor at time of screening and not receiving steroids and/or enzyme inducing ant-epileptic medications for brain metastases\n* Patient has participated in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer\n* Patient has a history of acute pancreatitis within 1 year of screening or a past medical history of chronic pancreatitis\n* Patient who relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease\n\nOther protocol-defined inclusion/esclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}